Skip to main content

Table 2 Clinical outcome

From: Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis

  Population (N = 291)
Relapses during study (n = 267)  
   No relapse 180 (67.4%)
   1 relapse 61 (22.8%)
   2 relapses 12 (4.5%)
   3 relapses 8 (3.0%)
   4–5 relapses 3 (1.1%)
Mean EDSS scores (n = 235)  
   Baseline 2.58 ± 1.45
   Study end 2.45 ± 1.52
   Change from baseline -0.13 ± 0.73*
  1. Data are presented as number of patients (%) for relapses and as mean ± SD for Expanded Disability Status Scale (EDSS) scores. The asterisk indicates a significant change from baseline (p < 0.05; Wilcoxon signed rank test).